{"id":"W2082863510","doi":"10.1111/j.1365-2141.2012.09232.x","title":"An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib","year":2012,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Onyx Pharmaceuticals; Exelixis; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Carfilzomib; Medicine; Bortezomib; Nausea; Refractory (planetary science); Proteasome inhibitor; Adverse effect; Multiple myeloma; Internal medicine; Regimen; Phases of clinical research; Oncology; Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000480173,0.0003149163,0.001538935,0.0003614553,0.0001127245,0.00006803144,0.0002851266,0.0001511989,0.00006767943],"category_scores_gemma":[0.0003530142,0.0002337438,0.00004100755,0.0002650601,0.0002267853,0.0007258237,0.0001033302,0.0004469676,0.000001452249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002190758,"about_ca_system_score_gemma":0.0001951588,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009906247,"about_ca_topic_score_gemma":0.002483604,"domain_scores_codex":[0.9967397,0.0005451684,0.001008685,0.0003691786,0.0006449128,0.0006923784],"domain_scores_gemma":[0.9973976,0.0001947123,0.0007497709,0.0003600993,0.0005974245,0.0007004187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02798405,0.06932086,0.8501759,0.0001228172,0.0007304808,0.0219776,0.001248706,0.000001428655,0.0006407889,0.000001008807,0.0001213893,0.02767495],"study_design_scores_gemma":[0.140496,0.1066003,0.7268609,0.001483831,0.00047005,0.02082867,0.001580315,0.00003965203,0.001266364,0.000001763294,0.00009249482,0.0002795956],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965135,0.00107154,0.0000135791,0.00003427681,0.00003897535,0.002163394,0.00004640106,0.00001408948,0.0001042156],"genre_scores_gemma":[0.9983135,0.00009727148,0.00126574,0.00004434099,0.00004177404,0.00004478236,0.00005715911,0.00006671128,0.00006871683],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.123315,"threshold_uncertainty_score":0.9531797,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04593809647162775,"score_gpt":0.3300050320972898,"score_spread":0.284066935625662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}